Exploiting Urine Derived DNA for the Assessment of Bladder Cancer using High Accuracy Sequencing
Description: NARRATIVE In bladder cancer, a relatively small number of genes are recurrently mutated, but challenges in exploiting the low frequency somatic mutations for clinical purposes remain. This project is designed to use urine derived DNA in conjunction with ultra-accurate sequencing to exploit the presence of these mutations to increase diagnostic and/or prognostic specificity of bladder cancer-associated mutations to track disease progression and determine treatment response. The end result will ultimately benefit bladder cancer patients by rapidly determining treatment response and/or effectiveness.
Funder: National Cancer Institute
Funding type: research
Funder scheme: R21
Start date: 2021-04-01
End date: 2024-03-31
Investigator: SCOTT ROBERT KENNEDY (lead)
Institution: University of Washington
Subfield: Cancer Research
Domain: Life Sciences
Funded outputs count: 7
Funder award ID: R21CA259780
OpenAlex ID: G738387875
